Most men come to me asking about sildenafil or tadalafil for one reason, and it isn't longevity. That's a perfectly good reason, and treating erectile dysfunction well is a meaningful part of what I do. But over the last few years a more interesting story has been building in the literature — one where this very familiar class of drugs keeps turning up next to lower rates of death, fewer cardiovascular events, and even a reduced risk of dementia. Patients are hearing pieces of this on podcasts and in longevity forums, usually without the caveats. So I want to walk through what the data actually shows, where it's strong, where it's soft, and who absolutely should not take these drugs.

Quick orientation first. The PDE5 inhibitor class includes sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra). They've been in wide use since sildenafil launched in 1998, which is part of why the longevity question is answerable at all — there are decades of prescribing data and very large populations to study.

The mechanism, and why it points beyond the bedroom

To understand the longevity signal, you have to understand what these drugs are actually doing at the cellular level — because it has very little to do with the penis specifically and a lot to do with blood vessels everywhere.

Your endothelium, the single-cell lining of every blood vessel in your body, releases nitric oxide. Nitric oxide activates an enzyme called guanylate cyclase, which produces a second messenger called cyclic GMP (cGMP). cGMP is the molecule that tells vascular smooth muscle to relax — that's vasodilation, improved blood flow, lower vascular resistance. The enzyme PDE5 exists to break cGMP back down and shut the signal off. A PDE5 inhibitor simply blocks that breakdown, so cGMP stays elevated and the vasodilatory signal persists.

In erectile tissue that produces an erection. But PDE5 and the nitric oxide–cGMP pathway exist throughout the vascular system, which is why the downstream effects extend well past sexual function. Sustained cGMP signaling has been associated with three things that matter for aging biology: vasodilation and improved endothelial function, antioxidant effects, and anti-proliferative and anti-inflammatory effects on the vessel wall. Long-term PDE5 inhibitor use has specifically been linked to lower levels of inflammatory markers like IL-6 in human studies.

If you think about what drives cardiovascular aging and vascular dementia — endothelial dysfunction, chronic low-grade inflammation, poor perfusion — this is a drug class acting directly on those upstream mechanisms. That's the biological rationale. It's plausible. Plausible is not the same as proven, so let's look at the outcome data.

The all-cause mortality and cardiovascular data

This is the strongest part of the story, and it's genuinely strong.

An early and frequently cited UK cohort followed nearly 6,000 men with type 2 diabetes — a population with high cardiovascular risk by definition — for around 7.5 years. Men prescribed a PDE5 inhibitor had roughly a 31% lower risk of all-cause mortality compared with non-users, and that association held up after adjusting for known confounders.

A 2024 systematic review and meta-analysis pulled this together across sixteen studies and over 1.25 million subjects. In men using PDE5 inhibitors for erectile dysfunction, the pooled risk of major adverse cardiovascular events (MACE) was significantly lower than controls — a relative risk of about 0.81. More recent large claims-based analyses in 2025 found the same pattern of reduced MACE, cardiovascular mortality, and all-cause mortality, and notably extended it into lower-risk men rather than only the sickest populations.

The consistency is the point. Different countries, different databases, different decades, and the arrow keeps pointing the same direction.

I want to be honest about the limitation, because it's a real one. Almost all of this is observational. Men who are prescribed and fill ED medication are, on average, healthier, more engaged with the healthcare system, and more physically active than men who aren't — and those traits independently lower mortality. Researchers adjust for what they can measure, but you cannot fully adjust away "this is a man who shows up to his appointments." We do not yet have a large randomized controlled trial powered for hard mortality endpoints. The evidence has been graded as moderate-certainty, not high. That's a meaningful signal worth discussing — not a settled fact to build a protocol around.

The dementia signal

Multiple large observational studies and meta-analyses have now reported an association between PDE5 inhibitor use and lower risk of Alzheimer's disease.

A 2024 study in Neurology reviewed records of roughly 270,000 men diagnosed with ED and found PDE5 inhibitor users were less likely to receive an Alzheimer's diagnosis over follow-up. A 2025 meta-analysis focused on sildenafil found roughly a two-fold lower risk of developing Alzheimer's among users (hazard ratio around 0.47). Other pooled analyses have reported similar magnitude reductions across the class.

The proposed mechanism fits the biology above — improved cerebral blood flow and reduced neuroinflammation. But here's the caveat I always give patients directly: an NIH study (DREAM) using a different methodology did not find a protective effect, and the strongest signals are specific to sildenafil rather than uniform across the class. This is hypothesis-generating, not practice-changing. No one should be taking sildenafil to prevent dementia on the strength of this. It's an interesting open question that deserves a real randomized trial, which researchers are actively pursuing.

Contraindications and interactions — the part that actually matters for your safety

Everything above is the optimistic half of the conversation. This is the half that keeps people safe, and it's non-negotiable.

Nitrates: the absolute contraindication

PDE5 inhibitors must not be combined with nitrate medications — nitroglycerin, isosorbide mononitrate or dinitrate, and recreational "poppers" (amyl nitrite). Both work through the nitric oxide–cGMP pathway, and stacking them can cause profound, dangerous hypotension. This is the single most important thing to understand about this drug class. If you have coronary artery disease and carry nitroglycerin, that is a conversation we have before anything is prescribed, not after. It's also worth noting that the interplay between nitrates and PDE5 inhibitors in cardiac patients is genuinely complex in the literature — at least one large registry signaled increased risk with combined use — which is exactly why this isn't a do-it-yourself decision.

Other meaningful interactions

Who needs careful evaluation first

Men with recent heart attack or stroke, unstable cardiovascular disease, significant low blood pressure, certain inherited retinal conditions (retinitis pigmentosa), or a history of NAION (a specific optic-nerve event) need individualized assessment before these drugs are appropriate. The well-known side effects — headache, facial flushing, nasal congestion, indigestion, transient visual changes, and the rare but urgent priapism — are mostly predictable extensions of the same vasodilatory mechanism.

How I think about this with patients

Here's where I land. If you have erectile dysfunction, a PDE5 inhibitor is a well-established, effective, generally well-tolerated treatment — and the emerging cardiovascular and cognitive data are a reassuring tailwind, not a reason for alarm. ED is also frequently an early marker of vascular disease elsewhere, so treating it is often a doorway to a broader cardiovascular and metabolic workup that's worth doing anyway.

The honest position is that this is a familiar, well-understood class of medication with a real and consistent signal toward better long-term outcomes, prescribed responsibly to the right person after the right questions are asked.

If you're curious whether this fits your situation, that's exactly the kind of thing worth talking through properly rather than self-prescribing from a forum thread.